menu
    • menu

    Company profile for Syntimmune

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Syntimmune is leveraging a deep understanding of FcRn biology to develop transformative therapies for patients with autoimmune diseases. The company has advanced rapidly into the clinic with its lead investigational candidate, a monoclonal antibody that rapidly inhibits pathogenic IgG and has potential as a pipeline-in-a-product in dermatology, rheumatology, hematology, neurology and nephrology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SyntimmuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    116 Huntington Ave, Suite 301 Boston, MA 02116
    Telephone
    Telephone
    617-206-4220
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.syntimmune.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Syntimmune Shareholders Win Again Over AZ, time for $181M
    Syntimmune Shareholders Win Again Over AZ, time for $181M

    13 Jun 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com//www.fiercepharma.com/pharma/astrazeneca-takes-181m-hit-syntimmune-shareholders-lawsuit-top-previous-130-award

    FIERCE BIOTECH
    13 Jun 2025
    Share Share
    AstraZeneca's Alexion Loses $130M To Syntimmune In Post-Merger Suit
    AstraZeneca's Alexion Loses $130M To Syntimmune In Post-Merger Suit

    09 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/after-2018-merger-azs-alexion-syntimmune-shareholders-win-130m-breach-contract-suit

    FIERCE PHARMA
    09 Sep 2024
    Share Share
    GSK submits its first application for daprodustat in Japan
    GSK submits its first application for daprodustat in Japan

    22 Aug 2019

    // ENDPTS

    https://endpts.com/gsk-submits-its-first-application-for-daprodustat-in-japan-two-drugmakers-part-with-15m-to-avoid-opioid-trial/

    ENDPTS
    22 Aug 2019
    Share Share
    Keeping up deal frenzy, Alexion strikes an RNAi pact
    Keeping up deal frenzy, Alexion strikes an RNAi pact

    25 Oct 2018

    // Andrew Dunn BIOPHARMA DIVE

    https://www.biopharmadive.com/news/alexion-dicerna-RNAi-research-deal/540472/

    Andrew Dunn BIOPHARMA DIVE
    25 Oct 2018
    Share Share
    Alexion doles out $22M upfront for two preclinical RNAi drugs from Dicerna
    Alexion doles out $22M upfront for two preclinical RNAi drugs from Dicerna

    24 Oct 2018

    // ENDPTS

    https://endpts.com/alexion-doles-out-22m-upfront-for-two-dicerna-preclinical-rnai-drugs/

    ENDPTS
    24 Oct 2018
    Share Share
    Alexion to Acquire Syntimmune
    Alexion to Acquire Syntimmune

    27 Sep 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180926005248/en

    BUSINESSWIRE
    27 Sep 2018
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search